CUE · Cue Biopharma Inc
United States · RS rating 52 · As of 2026-10-14
| Price | 18.60 USD |
|---|---|
| 1-day change | -5.0% |
| RS rating (overall / 1M / 3M / 12M) | 52 / 3 / 10 / 99 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 32 / 47 / 42 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +114.3% |
| Sales growth Q/Q | +921.0% |
| Distance from 52-week high | +50.9% |
| Market cap (USD) | $1.8M |